NEW YORK (GenomeWeb News) - Warnex Medical Laboratories will develop several new pharmacogenetic assays for Schering-Plough Canada, Warnex said last week.
 
Under the agreement, Warnex said it will supply pharmacogenetic and molecular biology services for Schering-Plough’s clinical trials for cancer and infectious disease therapeutics.
 
Warnex said the company is using its services to identify patients who are more likely to respond to a treatment or who are less likely to have an adverse event.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.